Skip to main content
Fig. 3 | BMC Infectious Diseases

Fig. 3

From: Impact of ITPA gene polymorphism for predicting anemia and treatment outcome in HCV infected patients taking Sofosbuvir Ribavirin therapy

Fig. 3

Hb reduction ≥ 2 g/dl from baseline to 1st month according to ITPA polymorphism. The height of bars presents the number of HCV infected patients with belong to each ITPA genotype experience hemoglobin reduction after weight-based ribavirin (for ˂75Kg weight 100 mg/day and > 75Kg body weight 1200 mg/day) was given

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us